Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multinational, Multicenter, Randomized, Double-Blind, Parallel-Group, Active-Control (Rater Blinded) Study, to Evaluate The Efficacy, Safety And Tolerability Of 2 Doses Of Oral Administration Of Laquinimod (0.6 mg/Day Or 1.2 mg/Day) Compared to Interferon ß-1a Administered Intra Muscular Once Weekly in Subjects With Relapsing Remitting Multiple Sclerosis (RRMS).

Next Previous
X
Search
Trial Profile

A Multinational, Multicenter, Randomized, Double-Blind, Parallel-Group, Active-Control (Rater Blinded) Study, to Evaluate The Efficacy, Safety And Tolerability Of 2 Doses Of Oral Administration Of Laquinimod (0.6 mg/Day Or 1.2 mg/Day) Compared to Interferon ß-1a Administered Intra Muscular Once Weekly in Subjects With Relapsing Remitting Multiple Sclerosis (RRMS).

Status: Withdrawn prior to enrolment
Phase of Trial: Phase III

Latest Information Update: 10 Nov 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Laquinimod (Primary) ; Interferon beta-1a
  • Indications Multiple sclerosis
  • Focus Biomarker; Pharmacogenomic; Therapeutic Use
  • Acronyms LIBRETTO
  • Sponsors Teva Branded Pharmaceutical Products R&D; Teva Pharmaceutical Industries

    • Most Recent Events

    • 23 Mar 2017 This trial has been Discontinued in UK (global end date-19-2-2014), according to European Clinical Trials Database.
    • 03 Mar 2014 Status changed from recruiting to withdrawn prior to recruitment as reported by ClinicalTrials.gov.
    • 19 Feb 2014 The trial will not proceed to the randomisation stage as decided by Teva Pharmaceuticals, as reported in a partner media release issued by Active Biotech. The trial design is no longer aligned with the regulatory strategy. Other trials are not impacted.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top